Specify a stock or a cryptocurrency in the search bar to get a summary
OKYO Pharma Ltd ADR
OKYOOKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. Address: 14/15 Conduit St, London, United Kingdom, W1S 2XJ
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OKYO
Dividend Analytics OKYO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OKYO
Stock Valuation OKYO
Financials OKYO
Results | 2019 | Dynamics |